Compare Stocks: NVCT, NAMS, SLS, and IRON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRON Disc Medicine	$55.74 -1.5%	$72.38	$40.00 ▼ $99.50	$2.17B	0.93	652,356 shs	430,712 shs
NAMS NewAmsterdam Pharma	$20.01 -0.9%	$24.49	$19.58 ▼ $42.21	$2.41B	0.1	1.72 million shs	2.19 million shs
NVCT Nuvectis Pharma	$18.00 -0.8%	$21.73	$5.55 ▼ $29.27	$592.49M	-0.24	213,931 shs	184,197 shs
SLS SELLAS Life Sciences Group	$11.88 -4.3%	$12.51	$1.39 ▼ $15.88	$2.51B	2.56	5.27 million shs	4.72 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRON Disc Medicine	-1.52%	-8.89%	-19.12%	-24.13%	-23.64%
NAMS NewAmsterdam Pharma	-0.89%	-9.58%	-10.51%	-35.56%	-47.15%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%
SLS SELLAS Life Sciences Group	-4.27%	+5.04%	+1.28%	+1.11%	+479.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRON Disc Medicine	$55.74 -1.5%	$72.38	$40.00 ▼ $99.50	$2.17B	0.93	652,356 shs	430,712 shs
NAMS NewAmsterdam Pharma	$20.01 -0.9%	$24.49	$19.58 ▼ $42.21	$2.41B	0.1	1.72 million shs	2.19 million shs
NVCT Nuvectis Pharma	$18.00 -0.8%	$21.73	$5.55 ▼ $29.27	$592.49M	-0.24	213,931 shs	184,197 shs
SLS SELLAS Life Sciences Group	$11.88 -4.3%	$12.51	$1.39 ▼ $15.88	$2.51B	2.56	5.27 million shs	4.72 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRON Disc Medicine	-1.52%	-8.89%	-19.12%	-24.13%	-23.64%
NAMS NewAmsterdam Pharma	-0.89%	-9.58%	-10.51%	-35.56%	-47.15%
NVCT Nuvectis Pharma	-0.83%	-11.29%	-22.91%	-3.23%	+198.51%
SLS SELLAS Life Sciences Group	-4.27%	+5.04%	+1.28%	+1.11%	+479.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRON Disc Medicine	2.77	Moderate Buy	$110.18	97.67% Upside
NAMS NewAmsterdam Pharma	2.85	Moderate Buy	$49.00	144.88% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	101.39% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-15.82% Downside

Current Analyst Ratings Breakdown

Latest NVCT, NAMS, SLS, and IRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/5/2026	NAMS NewAmsterdam Pharma	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$50.00 ➝ $42.00
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$39.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	IRON Disc Medicine	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$79.00 ➝ $86.00
9/10/2026	IRON Disc Medicine	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$120.00
9/10/2026	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
9/10/2026	IRON Disc Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$128.00
9/10/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$100.00
9/8/2026	NAMS NewAmsterdam Pharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$52.00
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	IRON Disc Medicine	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$88.00 ➝ $100.00

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRON Disc Medicine	N/A	N/A	N/A	N/A	$19.52 per share	N/A
NAMS NewAmsterdam Pharma	$22.50M	106.31	N/A	N/A	$5.97 per share	3.35
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRON Disc Medicine	-$212.18M	-$6.58	N/A	N/A	N/A	N/A	-37.17%	-33.65%	11/5/2026 (Estimated)
NAMS NewAmsterdam Pharma	-$203.82M	-$2.16	N/A	N/A	N/A	-3,644.21%	-34.81%	-31.50%	11/4/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest NVCT, NAMS, SLS, and IRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	SLS SELLAS Life Sciences Group	-$0.05	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	IRON Disc Medicine	-$1.63	N/A	N/A	N/A	$1.88 million	N/A
11/4/2026	Q3 2026	NAMS NewAmsterdam Pharma	-$0.4949	N/A	N/A	N/A	$7.54 million	N/A
11/3/2026	Q3 2026	NVCT Nuvectis Pharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/5/2026	Q2 2026	NAMS NewAmsterdam Pharma	-$0.4819	-$0.52	-$0.0381	-$0.52	$2.83 million	$3.70 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/30/2026	Q2 2026	IRON Disc Medicine	-$1.71	-$1.54	+$0.17	-$1.54	$1.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRON Disc Medicine	0.09	24.14	24.14
NAMS NewAmsterdam Pharma	N/A	9.03	9.03
NVCT Nuvectis Pharma	N/A	1.68	1.68
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRON Disc Medicine	83.70%
NAMS NewAmsterdam Pharma	89.89%
NVCT Nuvectis Pharma	96.77%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
IRON Disc Medicine	3.76%
NAMS NewAmsterdam Pharma	12.74%
NVCT Nuvectis Pharma	28.55%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRON Disc Medicine	165	38.39 million	36.95 million	Not Optionable
NAMS NewAmsterdam Pharma	100	119.54 million	104.31 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable

NVCT, NAMS, SLS, and IRON Headlines

Recent News About These Companies

SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH

October 11, 2026 | stocktwits.comS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

October 6, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 8.2% - What's Next?

October 1, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

October 1, 2026 | prnewswire.com

Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3

September 30, 2026 | insidermonkey.com

Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?

September 30, 2026 | finance.yahoo.com

SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data

September 30, 2026 | finance.yahoo.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Climb 6.3% - Should You Buy?

September 30, 2026 | marketbeat.com

SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data

September 30, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 29, 2026 | globenewswire.com

SELLAS Life Sciences präsentiert auf der AACR-Konferenz 2026 zu Bauchspeicheldrüsenkrebs präklinische Daten zur Wirksamkeit von SLS009 in Pankreaskrebsmodellen

September 26, 2026 | de.marketscreener.comD

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

September 25, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 24, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 22, 2026 | globenewswire.com

SELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

September 21, 2026 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

September 17, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 15, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 10, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 8, 2026 | globenewswire.com

SELLAS Life Sciences Group, Inc. (SLS)

September 4, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, NAMS, SLS, and IRON Company Descriptions

Disc Medicine NASDAQ:IRON

$55.74 -0.86 (-1.52%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$55.54 -0.20 (-0.36%)

As of 06:59 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$20.01 -0.18 (-0.89%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$20.32 +0.31 (+1.57%)

As of 06:59 AM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Nuvectis Pharma NASDAQ:NVCT

$18.00 -0.15 (-0.83%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$17.95 -0.05 (-0.28%)

As of 06:58 AM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

SELLAS Life Sciences Group NASDAQ:SLS

$11.88 -0.53 (-4.27%)

Closing price 10/14/2026 04:00 PM Eastern

Extended Trading

$11.80 -0.08 (-0.67%)

As of 07:08 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVCT, NAMS, SLS, and IRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVCT, NAMS, SLS, and IRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVCT, NAMS, SLS, and IRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, NAMS, SLS, and IRON Company Descriptions

Disc Medicine NASDAQ:IRON

NewAmsterdam Pharma NASDAQ:NAMS

Nuvectis Pharma NASDAQ:NVCT

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NVCT, NAMS, SLS, and IRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NVCT, NAMS, SLS, and IRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NVCT, NAMS, SLS, and IRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVCT, NAMS, SLS, and IRON Company Descriptions

Disc Medicine NASDAQ:IRON

NewAmsterdam Pharma NASDAQ:NAMS

Nuvectis Pharma NASDAQ:NVCT

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools